Precision medicine in practice: matching treatment to the individual

Averages treat populations; medicine treats people. Precision medicine uses genomic, molecular and clinical information to tailor prevention and treatment to the individual — and it has quietly moved from promise to implementation across oncology, pharmacogenomics and rare disease. A 2025 systematic review in the Journal of Translational Medicine examined how precision-medicine interventions are being implemented for non-communicable diseases, mapping the barriers, facilitators and strategies that shape real-world adoption.^[1]

What implementation actually requires

The science is necessary but not sufficient; the review literature consistently points to system factors:

• Testing pathways that flow. From sample to result to decision, turnaround and clarity determine whether genomic insight reaches the clinic visit that needs it.
• Decision support at the bedside. Clinicians need interpretation, not raw variants — pharmacogenomic guidance embedded in prescribing systems is a proven pattern.
• Workforce fluency. Every specialty now touches genomic information; baseline literacy plus accessible specialist support beats concentrating all knowledge in one clinic.
• Equitable access. Implementation planning that considers geography and resources keeps personalisation from becoming privilege.

The direction of travel

Costs of sequencing continue to fall, evidence linking variants to action continues to grow, and health systems increasingly treat molecular information as ordinary clinical data. The winners of this transition are institutions that build capability deliberately — and professionals who can bridge laboratory science, data interpretation and clinical care.

From the genome project to the clinic

The Human Genome Project’s completion in 2003 supplied the reference text; the two decades since have been about learning to read it usefully. Sequencing costs collapsed by orders of magnitude, turning a landmark scientific achievement into a routine clinical assay, and oncology led the way — imatinib’s success against chronic myeloid leukaemia showed early what happens when a therapy meets its molecular target, and tumour profiling now routinely steers treatment across cancer types. Pharmacogenomics matured alongside: well-characterised gene–drug interactions now inform dosing and drug choice, with clinical guidelines translating variants into concrete prescribing actions. Rare-disease diagnosis was transformed too, with genomic testing ending diagnostic odysseys that once lasted decades.

What separates promise from practice

The distance between a biomarker discovery and changed patient outcomes is institutional, and the systems that close it share features:

• Testing pathways that deliver in clinical time. Results arriving after the treatment decision are archaeology; turnaround, reporting clarity and reflex-testing protocols decide real-world utility.
• Molecular tumour boards and their analogues. Structured multidisciplinary interpretation — clinician, pathologist, geneticist, pharmacist — converting complex reports into defensible decisions.
• Informatics as the connective tissue. Variant knowledge bases, decision support in the record, and data feedback loops that let every treated patient teach the system.
• Equity engineered in. Reference data skewed toward some ancestries limits interpretive accuracy for others; broadening both research participation and testing access is a scientific necessity, not only a fairness one.
• A workforce fluent in genomics. Not every clinician a geneticist — but every prescriber able to read a pharmacogenomic note, and every institution holding genuine interpretive depth somewhere reachable.

Looking ahead

The definition keeps widening: multi-omics layering proteome and transcriptome onto genome, polygenic risk scores edging toward preventive use, and precision principles spreading from oncology into cardiology, psychiatry and beyond. The consistent bottleneck is translational capacity — the people and pathways that turn molecular information into better decisions. Institutions investing in that capacity now are building the standard of care their patients will soon expect.

Where EUSTM fits

The EUSTM Academy’s Professional Certification in Translational Medicine (PCTM) and Professional Certification in Health Data Science & Analytics (PCHDSA) together cover the pathway and the data craft on which personalised care depends.

Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.

← All Expert Insights